Unicycive rises as FDA accepts resubmitted filing for kidney drug

Shares of drug developer Unicycive Therapeutics UNCY.O rise 9.5% to $7.69 premarket

Co says FDA accepted for review its resubmitted application for oxylanthanum carbonate, a pill for high phosphate levels in dialysis patients

High phosphate levels occur in people with late‑stage kidney disease when the body cannot remove excess minerals, per co

 Co says FDA raised no initial concerns on safety or effectiveness; decision expected by June 27

 UNCY's drug aims to cut pill burden to help patients stay on treatment; possible launch later this year if approved, co says

Shares down ~27% in 2025